Försäljningsmässigt blev tredje kvartalet svagare än vi prognosticerat men resultatmässigt starkare.
Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s plann...
Redeye shares its initial take on TH1NG’s Q3 report, in which revenues were in line with our modest ...
SABCS (San Antonio Breast Cancer Symposium) is a major annual US cancer conference, and this year, B...
Redeye comments on Maximum Entertainment’s Q3-results which were weaker than expected.
Educational day with presentations from core holdings DP Patterning: small initial investment, large...
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.
Redeye provides a note about CLS’s TO7B outcome.
Today Absolent announced that Anders Hülse has been appointed new CEO and President of the group.
Vaxxa är ett e-handelsbolag som driver en digital auktionstjänst, där bolaget syftar till att erbjud...
Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
The largest office transaction YTD in Europe adds ~40% to topline Share issue at Q3 EPRA NRV a clear...
Redeye provides a preview for Integrum’s Q2 report, due on Wednesday, December 4.
Redeye provides a research update following the Pharmanovia’s decision to discontinue the partnershi...
ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.
This morning, it was announced that Serstech is carrying out a directed share issue amounting to SEK...
Embark Group har publicerat bolagets delårsrapport för det tredje kvartalet år 2024, som visade en s...
Redeye update its projections and valuation after Beyond Frames Q3 result.
Redeye briefly comments on Arise’s press release from earlier this week related to the settlement ag...
Strong sales growth in Q3, but 5% below our expectations We cut 2025e EBIT 1% but raise 2026e 4% on ...
